Phillip Md Et Al Frost Acquires 10,000 Shares of OPKO Health (OPK) Stock

OPKO Health (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 10,000 shares of the stock in a transaction on Thursday, April 5th. The shares were acquired at an average cost of $3.25 per share, with a total value of $32,500.00. Following the acquisition, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $9,974,090.75. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Tuesday, April 3rd, Phillip Md Et Al Frost bought 153,000 shares of OPKO Health stock. The shares were acquired at an average cost of $3.00 per share, with a total value of $459,000.00.
  • On Wednesday, March 28th, Phillip Md Et Al Frost bought 80,000 shares of OPKO Health stock. The shares were acquired at an average cost of $3.07 per share, with a total value of $245,600.00.
  • On Monday, March 26th, Phillip Md Et Al Frost bought 26,000 shares of OPKO Health stock. The shares were acquired at an average cost of $3.19 per share, with a total value of $82,940.00.
  • On Friday, March 23rd, Phillip Md Et Al Frost bought 25,000 shares of OPKO Health stock. The shares were acquired at an average cost of $3.27 per share, with a total value of $81,750.00.
  • On Wednesday, March 21st, Phillip Md Et Al Frost bought 30,000 shares of OPKO Health stock. The shares were acquired at an average cost of $3.38 per share, with a total value of $101,400.00.
  • On Monday, March 19th, Phillip Md Et Al Frost bought 40,000 shares of OPKO Health stock. The shares were acquired at an average cost of $3.51 per share, with a total value of $140,400.00.
  • On Thursday, March 15th, Phillip Md Et Al Frost bought 61,000 shares of OPKO Health stock. The shares were acquired at an average cost of $3.32 per share, with a total value of $202,520.00.
  • On Monday, March 12th, Phillip Md Et Al Frost bought 25,000 shares of OPKO Health stock. The shares were acquired at an average cost of $3.48 per share, with a total value of $87,000.00.
  • On Wednesday, March 7th, Phillip Md Et Al Frost bought 75,000 shares of OPKO Health stock. The shares were acquired at an average cost of $3.29 per share, with a total value of $246,750.00.
  • On Friday, March 2nd, Phillip Md Et Al Frost bought 364,800 shares of OPKO Health stock. The shares were acquired at an average cost of $2.94 per share, with a total value of $1,072,512.00.

Shares of OPK stock opened at $3.07 on Friday. OPKO Health has a 12-month low of $2.66 and a 12-month high of $7.90. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.98 and a current ratio of 1.14.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.04). OPKO Health had a negative net margin of 28.93% and a negative return on equity of 7.87%. The firm had revenue of $193.70 million during the quarter, compared to analyst estimates of $307.44 million. sell-side analysts anticipate that OPKO Health will post -0.48 EPS for the current fiscal year.

OPK has been the subject of a number of analyst reports. Zacks Investment Research raised shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Tuesday, December 12th. BidaskClub lowered shares of OPKO Health from a “sell” rating to a “strong sell” rating in a report on Wednesday, January 10th. ValuEngine lowered shares of OPKO Health from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Cantor Fitzgerald set a $20.00 price target on shares of OPKO Health and gave the company a “buy” rating in a report on Thursday, March 1st. Finally, JPMorgan Chase lowered shares of OPKO Health from a “neutral” rating to an “underweight” rating and set a $7.00 price target for the company. in a report on Friday, March 2nd. Four equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $11.29.

Hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company grew its holdings in shares of OPKO Health by 7.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,535 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 1,657 shares during the period. Ellington Management Group LLC bought a new stake in OPKO Health in the 4th quarter valued at $112,000. State of Alaska Department of Revenue bought a new stake in OPKO Health in the 4th quarter valued at $144,000. First Trust Advisors LP bought a new stake in OPKO Health in the 4th quarter valued at $154,000. Finally, Xact Kapitalforvaltning AB bought a new stake in OPKO Health in the 4th quarter valued at $179,000. 23.39% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Phillip Md Et Al Frost Acquires 10,000 Shares of OPKO Health (OPK) Stock” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/08/phillip-md-et-al-frost-acquires-10000-shares-of-opko-health-opk-stock.html.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Insider Buying and Selling by Quarter for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply